Supernus Pharmaceuticals (NASDAQ:SUPN) PT Lowered to $42.00

Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) had its target price trimmed by Piper Sandler from $43.00 to $42.00 in a report published on Wednesday, Benzinga reports. The firm currently has an overweight rating on the specialty pharmaceutical company’s stock. Separately, upgraded shares of Supernus Pharmaceuticals from a hold rating to a buy rating in […]

Leave a Reply

Your email address will not be published.

Previous post Neighbourly Pharmacy (TSE:NBLY) Price Target Lowered to C$20.50 at BMO Capital Markets
Next post DTE Energy (NYSE:DTE) Downgraded to “Sell” at